Trinity Biotech

Trinity Biotech FCF/Net Income

The Free Cash Flow to Net Income Ratio of Trinity Biotech (TRIB) as of Nov 9, 2026 is 32.51 %. In the previous year, Free Cash Flow to Net Income Ratio was 44.84 % — a change of -27.50% (lower).

FCF/Net Income

32.51 %

YoY

-27.50%

Last updated:

Free Cash Flow to Net Income Ratio of Trinity Biotech is 2025 32.51 % . Free Cash Flow to Net Income Ratio of Trinity Biotech was 2024 44.84 % . It decreases by -27.50% lower compared to the previous year.

The Trinity Biotech FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
-433.10 USD
Jan 1, 2019
243.02 USD
Jan 1, 2020
-212.23 USD
Jan 1, 2021
519.66 USD
Jan 1, 2022
16.82 USD
Jan 1, 2023
51.46 USD
Jan 1, 2024
44.84 USD
Jan 1, 2025
32.51 USD
The Trinity Biotech FCF/Net Income history
YEARFCF/Net IncomeYoY
32.51 %-27.50%
44.84 %-12.86%
51.46 %+205.89%
16.82 %-96.76%
519.66 %-344.86%
-212.23 %-187.33%
243.02 %-156.11%
-433.10 %-4,198.89%
10.57 %+25.00%
8.45 %-117.75%
-47.63 %+0.16%
-47.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Free Cash Flow to Net Income Ratio of Trinity Biotech is 32.51 % in 2025.

Free Cash Flow to Net Income Ratio of Trinity Biotech changed from 44.84 % to 32.51 %, representing a -27.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Trinity Biotech

All Key Metrics — Trinity Biotech